Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-21 vs AUROVELA FE 1.5/30
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).
Prevention of pregnancy in women who elect to use an oral contraceptive
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche (off-label but common use),Management of menstrual disorders (off-label): dysmenorrhea, menorrhagia, irregular bleeding,Hormonal contraception in patients with iron deficiency anemia (due to iron supplementation in formulation)
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
One tablet orally once daily at the same time each day for 28 consecutive days.
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Norethindrone: 5-14 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes hydroxylation and glucuronidation.
No dose adjustment required for mild to moderate renal impairment (GFR 30-89 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min/1.73 m²); use is not recommended.
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current data, but there is a small increased risk of cardiovascular and limb defects. Second and third trimester exposure has been associated with fetal harm including masculinization of female genitalia (due to progestin) and potential long-term effects. Use during pregnancy is not indicated; if pregnancy occurs, discontinue immediately.
Contraindicated in pregnancy. Use during first trimester associated with oral clefts and cardiac defects; second and third trimester exposure linked to feminization of male fetuses and other anomalies due to progestin effects. Increased risk of ectopic pregnancy. On-label indications exclude pregnancy use.
This triphasic oral contraceptive contains norethindrone and ethinyl estradiol. The 7/7/7-21 regimen uses three different hormone doses over 21 days followed by 7 placebo pills. Monitor for breakthrough bleeding, especially during dose transitions. Assess for contraindications including history of DVT, PE, migraine with aura, breast cancer, liver disease, or age >35 with smoking. Consider CYP3A4 interactions; rifampin, certain anticonvulsants, and St. John's wort may reduce efficacy.
AUROVELA FE 1.5/30 is a combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg. It contains ferrous fumarate as an iron supplement in the placebo pills. Patients with a history of venous thromboembolism, thrombogenic mutations, or estrogen-sensitive malignancies should not use this medication. Baseline blood pressure, lipid profile, and liver function tests are recommended. Counsel patients to take at the same time daily to maintain efficacy. Consider drug interactions with antibiotics, anticonvulsants, and St. John's Wort which may reduce contraceptive effectiveness.
No interactions on record
No interactions on record
ORTHO-NOVUM 7/7/7-21 and AUROVELA FE 1.5/30 are distinct pharmacological agents. ORTHO-NOVUM 7/7/7-21 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy in women who elect to use an oral contraceptive. AUROVELA FE 1.5/30 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy (FDA-approved)Treatment of moderate acne vulgaris in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche (off-label but common use)Management of menstrual disorders (off-label): dysmenorrhea, menorrhagia, irregular bleedingHormonal contraception in patients with iron deficiency anemia (due to iron supplementation in formulation). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. ORTHO-NOVUM 7/7/7-21 carries a safety status of Category C, whereas AUROVELA FE 1.5/30 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Norethindrone acetate is metabolized primarily in the liver via reduction and conjugation (sulfation and glucuronidation). It is a prodrug, rapidly hydrolyzed to norethindrone. Ethinyl estradiol is metabolized via CYP3A4 in the liver, undergoing hydroxylation, methylation, and conjugation (glucuronidation and sulfation). Both undergo enterohepatic recirculation.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Renal: ~50-60% as metabolites, <10% unchanged; Fecal: ~40-50% via bile; Ethinyl estradiol undergoes enterohepatic recirculation.
Ethinyl estradiol: 95-98% bound to albumin and SHBG; norethindrone: 60-70% bound to SHBG and albumin.
Norethindrone: ~97% (albumin and SHBG); Ethinyl estradiol: ~97-98% (albumin, not SHBG).
Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 3.5-5 L/kg; indicates extensive tissue distribution.
Norethindrone: 2-5 L/kg (extensive tissue distribution); Ethinyl estradiol: 2-4 L/kg (distributes into breast milk and body fat).
Oral: ~40-50% for ethinyl estradiol (first-pass metabolism); ~60-70% for norethindrone.
Oral: Norethindrone ~64% (first-pass effect); Ethinyl estradiol ~40-45% (extensive first-pass metabolism).
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; no specific dose adjustment, but monitor for signs of hepatic toxicity.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution and monitor liver function in mild to moderate impairment (Child-Pugh A/B); consider alternative methods if liver function deteriorates.
Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults. Weight-based adjustments not established; use standard adult regimen.
Not indicated for use before menarche.
Not indicated for postmenopausal women. Use in perimenopausal women: standard dosing with consideration of increased thrombotic risk and comorbidities.
Not indicated for use in postmenopausal women. No specific studies in elderly; consider age-related risks of thromboembolism and cardiovascular disease.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years of age, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
No significant food interactions. Grapefruit juice may increase estrogen exposure; avoid large amounts. Taking with food can reduce nausea.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No other significant food interactions. Take with food or milk to reduce gastrointestinal upset if needed.
Combined hormonal contraceptives may reduce milk production and quality, especially in early postpartum. Small amounts of estrogen and progestin are excreted in breast milk; the M/P ratio is not well defined for this specific formulation. Use is generally not recommended during breastfeeding, particularly before weaning or beyond 6 weeks postpartum when milk supply is established. Alternatives (progestin-only) are preferred.
Excreted in breast milk; M/P ratio unknown. May reduce milk production and alter composition. Use only if benefits outweigh risks, with monitoring for infant jaundice and weight gain. Consider alternative contraception during breastfeeding.
Not applicable; this drug is contraindicated during pregnancy. No dose adjustments are made for pregnancy as it is not used in that setting. Pharmacokinetic changes of pregnancy (e.g., increased clearance) are not relevant because use is avoided.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as therapy should be discontinued immediately if pregnancy occurs.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Start pack on first day of period or first Sunday after; use backup contraception for first 7 days if starting later.,Common side effects: nausea, breast tenderness, breakthrough bleeding; usually improve within 3 cycles.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects.,Seek emergency care if signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,Some medications (antibiotics, seizure meds, St. John's wort) may decrease effectiveness; inform all healthcare providers.
Take one tablet daily at the same time each day, with or without food.,Swallow tablets whole; do not crush or chew.,Missed dose management: if missed by less than 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and continue with next tablet; use back-up contraception if multiple doses missed.,Common side effects include nausea, breast tenderness, weight changes, and breakthrough bleeding; these may improve after 2-3 cycles.,Seek immediate medical attention if you experience leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Inform your healthcare provider of all medications, including over-the-counter drugs and herbal supplements.,Continue taking the iron-containing placebo tablets during the placebo week; do not skip.